Hims & Hers (HIMS) is down -6.1%, or -$1.89 to $29.16.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Morgan Stanley says Hims branded tirzepatide margins likely well below compounds
- Sell Rating for Hims & Hers Health Due to High Pricing and Limited Market Penetration of New Offerings
- Cautious Outlook on Hims & Hers Health Amid Expansion and Margin Concerns
- Citi sees high price of Tirzepatide on Hims & Hers being ‘prohibitive’
- Sell Rating for Hims & Hers Health Amid Low Margin Concerns and Competitive Pricing